Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost
Tharimmune Announces Expanded Role as Super Validator on Canton Network
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Tharimmune (NASDAQ:THAR) Stock Price Down 4.1% – Here’s What Happened
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
Tharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Tharimmune to Present at the Microcap Conference 2025
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune Announces Upcoming Conference Presentations
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune Announces Upcoming Conference Presentations
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Why Is Tharimmune (THAR) Stock Moving Today?
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics